Stay updated with breaking news from Trial Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The trial program under way right now. to run a growing business, is to be on a journey. and along the ride, you'll find many challenges. your dell technologies advisor is here to help. so you can stop at nothing for your customers.
An accurate assessment of a patient's kidney function is critical for determining eligibility for anticancer treatments. In a paper published today in...
ABBVie announced today that the European Commission has approved VENCLYXTO ® in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. 1 The approval is valid in all 27 member states of the EU, as well as Iceland Liechtenstein and Norway . “VENCLYXTO has proven incremental … – ABBVie (NYSE: ABBV) announced today that the European Commission (EC) has approved VENCLYXTO ® (venetoclax) in combination with a hypomethylating agent, azacitidine or d...
ABBVie today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for VENCLYXTO® in combination with hypomethylating agents for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. The positive CHMP opinion is a scientific recommendation for marketing authorization to the … ABBVie (NYSE: ABBV) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for VENCLYXTO...
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma Amgen and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroid dose, without loss of asthma control, with tezepelumab compared to placebo. The 48-week trial assessed the efficacy and safety of the potential new medicine tezepelumab compared to placebo in 150 severe asthma patients who required maintenance use of oral … Amgen (NASDAQ:AMGN) and AstraZeneca today announced the SOURCE tria...